Stock Analysis
Theraclion (EPA:ALTHE) Full Year 2023 Results
Key Financial Results
- Revenue: €3.92m (up 217% from FY 2022).
- Net loss: €3.68m (loss narrowed by 26% from FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
In the last 12 months, the only revenue segment was Surgical & Medical Equipment contributing €3.92m. The largest operating expense was General & Administrative costs, amounting to €5.73m (79% of total expenses). Explore how ALTHE's revenue and expenses shape its earnings.
Theraclion shares are up 2.2% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 4 warning signs for Theraclion (1 makes us a bit uncomfortable!) that you need to be mindful of.
Valuation is complex, but we're helping make it simple.
Find out whether Theraclion is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALTHE
Theraclion
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system.
Adequate balance sheet with weak fundamentals.
